Description_x000D_ Packaging_x000D_ 5, 25 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ PF-06672131 is a selective EGFR kinase inhibitor thought to covalently react with active-site cysteine residues in the ATP binding pocket. PF-06672131 has been used as a probe for proteomic analysis to identify off-target binding substrates. The dimethylaminomethyl (DMAM) group appears to increase compound stability in cancer cells with a resultant increase in protein reactivity from selective EGFR binding to widespread proteome-wide reactivity after treatment._x000D_ Other Notes_x000D_ This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer._x000D_ To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Legal Information_x000D_ Sold for research purposes under agreement from Pfizer Inc._x000D_ Pfizer is a registered trademark of Pfizer, Inc.